Asmerom Sengal

Molecular Oncology/Pathology Gynaecological Oncology

[Asmerom Sengal @ATSengal]

Protect Kids: End Gender Ideology in Victorian Schools - Click here: https://t.co/BDbWZxDIsI

[Asmerom Sengal @ATSengal]

I feel honoured to to be awarded the #CureCancer ROTY2024 finalist. https://t.co/oERabQNFNV

[Cure Cancer @CureCancerAu]

Congratulations to our brilliant Cure Cancer 2024 Researcher Of The Year Award winners 🔬🧡

We celebrated the groundbreaking work Dr Asmerom Sengal & Dr Marjan Naeini who were honoured as finalists, & Dr Yuchen Feng was named Researcher of the Year 2024!

https://t.co/zl7U5UskoE

[Asmerom Sengal @ATSengal]

Bini made history. He won the Surf Coastal Classic 2024 in Australia. Proud of you https://t.co/ruttcfDH5e

[Asmerom Sengal @ATSengal]

@AAsemrom A fake claim and he failed to fabricate the drama.

[Asmerom Sengal @ATSengal]

https://t.co/RRCliYxowX

[Asmerom Sengal @ATSengal]

Happy to share our recent paper which was published in Nature Precision Oncology last week. The study opens a new avenue of personalised treatment options for endometrial cancer patients. https://t.co/9zHasuTEEJ

[Asmerom Sengal @ATSengal]

#Endometrialcancer is an exception with a trend of remarkable increase in both incidence and mortality. It's less funded and researched. Tomorrow at 12:30PM local time a "Lunch and Learn" session will be held hosted by #CureCancer to increase awareness https://t.co/ZIqXnRgq9t

[Asmerom Sengal @ATSengal]

Excited to join the @PLOSONE Editorial Board, an #OpenScience journal publishing trusted research in over 200 subject areas across science, engineering, medicine and the related social sciences and humanities.

[Asmerom Sengal @ATSengal]

Our recent paper submitted in #natureprecisiononcology coming out in preprint. #FGFR2c as novel target therapy in #endometrialcancer.

[Cure Cancer @CureCancerAu]

Erratum: We are funding 13 researchers for 2023 🔬

[Asmerom Sengal @ATSengal]

Delighted to be one of the Cure Cancer ECR grant scheme 2023 awardee. Thank you #CureCancer for the generous support to fund cutting edge research. https://t.co/KiZbRiPD6W

[Cure Cancer @CureCancerAu]

🎉💜 World Cancer Day Announcement

We're funding 14 brilliant cancer researchers in 2023!

Thanks to your support, we're funding innovative research for those affected by cancer.

Check out our researchers: https://t.co/abT0vu4n7m

#WorldCancerDay #CancerResearch

[Sirak Bahlbi @SirakBahlbi]

If #Eritrea can produce a world beating athletes in sports that require heavy investment and long term strategy under tremendous amount of existential national threat; imagine the possibilities if it were free to reach its potential @GrmayeBiniam #EritreaPrevails

[Asmerom Sengal @ATSengal]

@martinplaut We have a very descriptive proverb in our local language that matches your propaganda about #Eritrea and Ethiopia " nadgi zeykebedos nmetsan kebedo" literally means a load that doesn't overload a donkey overloads for a robe

[Asmerom Sengal @ATSengal]

@AtvAsena It is not possible to save a dead wolf.

[Asmerom Sengal @ATSengal]

Our paper has recently been published in the Journal of Pathology: Clinical Research. In this article, we have demonstrated the role of the two #FGFR2 splice isoforms (FGFR2b and FGFR2c) in stratifying #endometrial #cancer.
https://t.co/rB4ITBvjbA

[Asmerom Sengal @ATSengal]

https://t.co/ijC7cPAEZ7

[Asmerom Sengal @ATSengal]

@anzgog @BnePam I am thrilled to be part of #ANZGOG ASM, pure science symposium speaker. "pathaways to Precision Care" Targeting with #FGFR inhibitors in #endometrialcancer preclinical models with #FGFR2 splice isoform switching. A novel finding

[ANZGOG @anzgog]

Next up is Dr Asmeron Sengal from A/Prof @BnePam
's group presenting on the role of FGFR2 dysregulation (isoform switching) in endometrial cancer & the efficacy of FGFR inhibition in endometrial cancer patient derived models with FGFR2c splice isoform expression #ANZGOG2022ASM

[Asmerom Sengal @ATSengal]

@djmarsh24 @anzgog @DrCFord @nikolabowden Generally, the sessions were great but it was not fair not giving equal allocated time for Q&A for all prsenters when mediating the session.